UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Affective temperament, fatigue, and pain in cancer patients

Journal of affective disorders, 2023-11, Vol.340, p.80-87

2023

Volltextzugriff (PDF)

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response

Annals of hematology, 2020-11, Vol.99 (11), p.2599-2609

2020

Volltextzugriff (PDF)

Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5

Journal of Immunology, 2006-02, Vol.176 (3), p.1759-1768

2006

Volltextzugriff (PDF)

Immunoglobulin light chain amyloidosis: Short tutorial in screening, early detection, risk assessment and response evaluation

Memo - Magazine of European medical oncology, 2021-03, Vol.14 (1), p.103-110

2021

Volltextzugriff (PDF)

Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance

Memo - Magazine of European medical oncology, 2021-03, Vol.14 (1), p.80-88

2021

Volltextzugriff (PDF)

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders

Blood, 2004-11, Vol.104 (11), p.4754-4754

2004

Volltextzugriff (PDF)

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis

Blood, 2006-11, Vol.108 (11), p.4323-4323

2006

Volltextzugriff (PDF)

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML

Blood, 2006-11, Vol.108 (11), p.1901-1901

2006

Volltextzugriff (PDF)

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis

Blood, 2004-11, Vol.104 (11), p.4755-4755

2004

Volltextzugriff (PDF)

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

American journal of hematology, 2022-04, Vol.97 (4), p.390-400

2022

Volltextzugriff (PDF)

Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms

American journal of hematology, 2023-05, Vol.98 (5), p.770-783

2023

Volltextzugriff (PDF)

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

American journal of hematology, 2017-09, Vol.92 (9), p.885-891

2017

Volltextzugriff (PDF)

In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di- N -oxide Derivatives against Trypanosoma cruzi as Trypanothione Reductase Inhibitors

International journal of molecular sciences, 2022-11, Vol.23 (21), p.13315

2022

Volltextzugriff (PDF)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

Cancers, 2021-11, Vol.13 (23), p.5886

2021

Volltextzugriff (PDF)

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

The lancet oncology, 2019-06, Vol.20 (6), p.781-794

2019

Volltextzugriff (PDF)

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood, 2018-08, Vol.132 (7), p.694-706

2018

Volltextzugriff (PDF)

Paraneoplastic autoimmune thrombocytopenia in solid tumors

Critical reviews in oncology/hematology, 2012-01, Vol.81 (1), p.75-81

2012

Volltextzugriff (PDF)

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

Hematology (Luxembourg), 2024-12, Vol.29 (1), p.2311600-2311600

2024

Volltextzugriff (PDF)

Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors

Molecules (Basel, Switzerland), 2017-02, Vol.22 (2), p.220-220

2017

Volltextzugriff (PDF)

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

Journal of cancer research and clinical oncology, 2021-01, Vol.147 (1), p.205-212

2021

Volltextzugriff (PDF)

The postoperative splenic/portal vein thrombosis after splenectomy and its prevention - an unresolved issue

Haematologica (Roma), 2008-08, Vol.93 (8), p.1227-1232

2008

Volltextzugriff (PDF)

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

British journal of haematology, 2014-03, Vol.164 (6), p.822-833

2014

Volltextzugriff (PDF)

Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain‑2 for the Treatment of Neglected Tropical Diseases (NTDs)

Journal of medicinal chemistry, 2017-08, Vol.60 (16), p.6911-6923

2017

Volltextzugriff (PDF)

1 – 25 von 174

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(166)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Englisch
(172)
Deutsch
(1)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(92)
Humans
(68)
Hematology
(36)
Female
(31)
Oncology
(31)
Animals
(27)
Male
(26)
Biological And Medical Sciences
(24)
Medical Sciences
(23)
Adult
(22)
Middle Aged
(21)
Aged
(18)
Multiple Myeloma
(15)
Medicine
(14)
Medicine & Public Health
(14)
Mice
(13)
Patients
(13)
Hematologic And Hematopoietic Diseases
(12)
Immunology
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis

Affective temperament, fatigue, and pain in cancer patients

Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response

Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5

Immunoglobulin light chain amyloidosis: Short tutorial in screening, early detection, risk assessment and response evaluation

Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML

Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis

PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms

Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant‐ineligible patients with newly diagnosed multiple myeloma

Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms

Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease

In Vitro and In Silico Analysis of New n-Butyl and Isobutyl Quinoxaline-7-carboxylate 1,4-di- N -oxide Derivatives against Trypanosoma cruzi as Trypanothione Reductase Inhibitors

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Paraneoplastic autoimmune thrombocytopenia in solid tumors

Renal outcome in multiple myeloma patients with cast nephropathy: a retrospective analysis of potential predictive values on clinical and renal outcome

Trypanocidal Activity of Quinoxaline 1,4 Di-N-oxide Derivatives as Trypanothione Reductase Inhibitors

Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers

The postoperative splenic/portal vein thrombosis after splenectomy and its prevention - an unresolved issue

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

Development of Novel Peptide-Based Michael Acceptors Targeting Rhodesain and Falcipain‑2 for the Treatment of Neglected Tropical Diseases (NTDs)

Suchergebnisse filtern